Nano-X Imaging（NNOX）株式概要
Nano-X Imaging Ltd.は、デジタルX線源を搭載した商用グレードの断層撮影装置を開発している。 詳細
NNOX Community Fair Values
Create NarrativeSee what 64 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nano-X Imaging Ltd. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.90 |
| 52週高値 | US$5.26 |
| 52週安値 | US$0.73 |
| ベータ | 1.23 |
| 1ヶ月の変化 | -17.78% |
| 3ヶ月変化 | -51.82% |
| 1年変化 | -82.77% |
| 3年間の変化 | -92.86% |
| 5年間の変化 | -96.84% |
| IPOからの変化 | -95.87% |
最新ニュース
ナラティブ更新 • Jul 15
NNOX: Restructuring And Outsourced Production Will Drive Future Rebound Potential
Analysts have trimmed their price target on Nano-X Imaging by $2, reflecting updated assumptions for fair value at $7.4, a slightly higher discount rate of 8.58%, revised revenue growth expectations of 94.80%, a lower projected profit margin of 6.12%, and a higher future P/E of 122.52. What’s in the News for Nano-X Imaging Multiple law firms filed securities fraud class action lawsuits against Nano-X Imaging Ltd.
ナラティブ更新 • Jul 01
NNOX: Legal Overhang May Set Stage For Future Upside Repricing
Nano-X Imaging's analyst price target has been revised to $5.80 from $6.65. Analysts point to updated fair value estimates, a slightly higher discount rate, adjusted revenue growth assumptions, an updated profit margin outlook, and a lower future P/E multiple to support the change.Recent updates
ナラティブ更新 • Jul 15
NNOX: Restructuring And Outsourced Production Will Drive Future Rebound Potential
Analysts have trimmed their price target on Nano-X Imaging by $2, reflecting updated assumptions for fair value at $7.4, a slightly higher discount rate of 8.58%, revised revenue growth expectations of 94.80%, a lower projected profit margin of 6.12%, and a higher future P/E of 122.52. What’s in the News for Nano-X Imaging Multiple law firms filed securities fraud class action lawsuits against Nano-X Imaging Ltd.ナラティブ更新 • Jul 01
NNOX: Legal Overhang May Set Stage For Future Upside Repricing
Nano-X Imaging's analyst price target has been revised to $5.80 from $6.65. Analysts point to updated fair value estimates, a slightly higher discount rate, adjusted revenue growth assumptions, an updated profit margin outlook, and a lower future P/E multiple to support the change.Seeking Alpha • Jun 26
Nano-X Withdraws Guidance, Signals Rocky Road Ahead
Summary Nano-X Imaging Ltd. is downgraded to a sell as its narrative shifts from disruptive growth to execution and survival. NNOX's Q1 revenue rose 53% to $4.3M, but core Nanox.ARC hardware contributed minimally; most revenue stems from teleradiology and AI/Health IT. Withdrawn FY26 guidance, persistent cash burn, and explicit going concern warnings highlight severe liquidity and execution risks. Despite early commercial traction and partnerships, delayed deployments and a shrinking cash runway make near-term dilution highly likely. Read the full article on Seeking Alpha
ナラティブ更新 • Jun 17
NNOX: New Distribution Agreements Will Support Future Stock Upside Potential
Analysts have reduced their Nano-X Imaging price target by $2 to reflect updated assumptions around long term revenue growth, profit margins, and future P/E multiples. What’s in the News for Nano-X Imaging Nano-X Imaging signed a U.S. distribution agreement through its subsidiary Nanox Impact Inc.ナラティブ更新 • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.ナラティブ更新 • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.ナラティブ更新 • Apr 12
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).ナラティブ更新 • Mar 28
NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.ナラティブ更新 • Mar 12
NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.ナラティブ更新 • Feb 25
NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).ナラティブ更新 • Feb 10
NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.ナラティブ更新 • Jan 27
NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).ナラティブ更新 • Jan 12
NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.ナラティブ更新 • Dec 26
NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.ナラティブ更新 • Dec 12
NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).分析記事 • Oct 31
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブ更新 • Aug 15
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.分析記事 • May 27
Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
One thing we could say about the analysts on Nano-X Imaging Ltd. ( NASDAQ:NNOX ) - they aren't optimistic, having just...
新しいナラティブ • Apr 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.分析記事 • Apr 01
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 14
Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Summary Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system. Expect Nano-X to reach inflection point for revenue growth due to FDA approvals and the huge need for cost-effective X-ray monitoring and analyzing solutions. Read the full article on Seeking AlphaSeeking Alpha • Jan 04
Nano-X Imaging's Recent Surge Is Undeserved
Summary Nano-X Imaging shares surged 50.8% in a month, but I maintain a "sell' rating due to overvaluation and poor fundamentals. Despite some positive developments, Nano-X generates minimal revenue, significant net losses, and cash outflows, necessitating future capital raises. Recent FDA clearances and accolades are promising, but there's no concrete evidence that their technologies will achieve commercial success. The company's declining net cash balance and unjustified valuation reinforce my bearish stance on Nano-X Imaging. Read the full article on Seeking Alpha分析記事 • Dec 05
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Key Insights Nano-X Imaging to hold its Annual General Meeting on 10th of December Total pay for CEO Erez Meltzer...分析記事 • Nov 25
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Sep 29
Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Summary Nano-X Imaging has seen a significant decline in stock value, shedding over 37% since February, with no strong catalysts to reverse the trend. Nvidia’s small stake in Nano-X briefly boosted the stock, but without further investment or partnership, investor excitement has waned. Persistent financial losses, slow revenue growth, and limited global reach make Nano-X a high-risk investment with potential for further value erosion. Read the full article on Seeking Alpha分析記事 • Apr 05
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 01
Nano-X Imaging: System Deployments Finally Begin
Summary Nano-X Imaging is executing its long-awaited roll-out strategy with multiple Nanox.ARC system deployments in the U.S. The company has also made progress in Africa and Latin America with installations and distribution agreements. However, financial performance is still lagging with scant details on how Nano-X will scale up to commercial scale. The story is improving, but there are still too many concerns for me to invest in NNOX stock. Read the full article on Seeking Alpha株主還元
| NNOX | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -20.0% | -0.3% | -1.0% |
| 1Y | -82.8% | 38.5% | 14.7% |
業界別リターン: NNOX過去 1 年間で38.5 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: NNOXは、過去 1 年間で14.7 % のリターンを上げたUS市場を下回りました。
価格変動
| NNOX volatility | |
|---|---|
| NNOX Average Weekly Movement | 18.5% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: NNOXの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: NNOXの 週次ボラティリティ は、過去 1 年間で13%から18%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2011 | 197 | Erez Meltzer | www.nanox.vision |
Nano-X Imaging Ltd.は、デジタルX線源を搭載した商用グレードの断層撮影装置を開発している。同社は、遠隔画像診断サービスを提供し、実際の医療画像アプリケーションで使用される人工知能アプリケーションを開発している。同社のソリューションには、デジタルX線源を組み込んだ医療用断層画像システムNanox.ARCを構成するNanox Multi Source System、Nanox CLOUDは、医療画像を放射線科医にマッチングさせるマッチングエンジンを採用したプラットフォームで、画像レポジトリ、診断支援AIシステムへの接続、課金、レポーティングを提供する。また、画像診断施設と放射線科医を接続し、放射線科医を可能にするNanox.MARKETPLACE、地域の規制承認を受けるためのNanox.CONNECTも提供している。CONNECTは、現地の規制当局の承認を受け、ビジネスモデルとサービスの可能性を調査・評価する。人工知能（AI）ベースのソフトウェア画像ソリューションは、病院、医療維持機関、統合配送ネットワーク、製薬会社、保険会社に提供され、既存のコンピュータ断層撮影スキャンのデータのマイニングを通じて、診断されていない、または診断が不十分な病状を特定または予測するように設計されている。テレラジオロジーサービスは、放射線診療所、病院、診療所、画像診断センター、移動画像サービスプロバイダー、緊急医療施設、複数の専門医グループに画像解釈サービスを提供する。また、骨粗鬆症ケア管理ソフトウェアプラットフォーム「Real+ Osteoporosis Care Management Platform」、人工知能ベースのソリューション「AI-Based Aortic Valve Calcification Measurement」、人工知能ベースの体組成分析機能「AI-Based Body Composition Measurement」、病院やその他の医療機関にサービスを提供する医療情報技術サービスプロバイダー「Nanox Health IT」を提供している。Nano-X Imaging Ltd.は2011年に設立され、イスラエルのペタティクバに本社を置いている。
Nano-X Imaging Ltd. 基礎のまとめ
| NNOX 基礎統計学 | |
|---|---|
| 時価総額 | US$62.38m |
| 収益（TTM） | -US$76.04m |
| 売上高(TTM) | US$14.52m |
4.3x
P/Sレシオ-0.8x
PER（株価収益率NNOX は割高か？
公正価値と評価分析を参照収益と収入
| NNOX 損益計算書（TTM） | |
|---|---|
| 収益 | US$14.52m |
| 売上原価 | US$26.84m |
| 売上総利益 | -US$12.33m |
| その他の費用 | US$63.72m |
| 収益 | -US$76.04m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.09 |
| グロス・マージン | -84.91% |
| 純利益率 | -523.83% |
| 有利子負債／自己資本比率 | 2.4% |
NNOX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/26 19:15 |
| 終値 | 2026/07/24 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Nano-X Imaging Ltd. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Ravi Misra | Berenberg |